Debug Stats | ### Total Build Time: 14 ms 23.539 KB CONCEPT_NAME gt=1 ms Completed: 1 ms rowSize= 344 bytesCONCEPT_SOLR_HIT_STATS gt=0 Completed: 0 ms rowSize= 14 bytesCONCEPT_DEFINITION gt=0 Completed: 0 ms rowSize= 235 bytes- Skipping details on:
CONCEPT_SYNONYM gt=NONE 0 Completed: 0 ms rowSize= 0 bytes - Skipping details on:
CONCEPT_TEXT gt=NONE 0 Completed: 0 ms rowSize= 0 bytes CONCEPT_SEMANTIC_TYPE gt=0 Completed: 0 ms rowSize= 14 bytes- Skipping details on:
CONCEPT_NAMESPACE gt=NONE 0 Completed: 0 ms rowSize= 0 bytes CONCEPT_PARENTS gt=0 Completed: 0 ms rowSize= 7 bytesCONCEPT_CHILDREN gt=0 Completed: 0 ms rowSize= 8 bytesCONCEPT_ANCESTRAL_ROOTS gt=0 Completed: 0 ms rowSize= 15 bytesCONCEPT_RELATIONSHIPS gt=2 ms Completed: 2 ms rowSize= 106 bytesCONCEPT_GENES gt=9 ms Completed: 9 ms rowSize= 21.643 KBCONCEPT_XREFS gt=2 ms Completed: 2 ms rowSize= 1.157 KBCONCEPT_ANCILLARY gt=0 Completed: 0 ms rowSize= 14 bytes- Reload Stats
|
Genes (9)
Species: human : 9 | |
Human | BRCA3 | 60500 | breast cancer 3 | Malignant mixed mullerian tumor of the ovary and bilateral breast cancer: an argument for BRCA3, or a coincidental cluster of unconnected cancers? | Human | CHEK2 | 11200 | checkpoint kinase 2 | CHEK2 germ line mutation is associated with bilateral breast cancer | Human | TP53 | 7157 | tumor protein p53 | analysis of 31 bilateral breast cancer (biBC) pairs (12 synchronous & 19 metachronous cases); TP53 sequence alterations were detected in 7 patients; 2 had mutations in both neoplasms & in 5 biBC pairs the TP53 gene was affected in only 1 of the tumors | Human | RAD51 | 5888 | RAD51 recombinase | Identification of Rad51 alteration in patients with bilateral breast cancer. | Human | KIF22 | 3835 | kinesin family member 22 | RESULTS: The mRNA level of KNSL4 was significantly lower in the cases at stages iii-iv than in the cases at stages iii-iv(P_lt_0.001), significantly lower in the cases with more than 3 metastastic lymph nodes than in the cases with 0-3 metastastic positive lymph nodes (P_lt_0.01), slighly lower in the cases with negative estrogen receptor or prognesterone receptor than in the cases with positive receptors (P>0.05), lower in the 6 cases with distant metastasis than in the rest cases without distant metastasis within 24 month follow up, lower in the 3 cases with bilateral breast cancer than in other cases with unilateral breast cancer, and significantly lower in c-erbB-2-positive group than in c-erB-2-negative group ,P_lt_0.01). | Human | DRD2 | 1813 | dopamine receptor D2 | Linkage analysis of DRD2, a marker linked to the ataxia-telangiectasia gene, in 64 families with premenopausal bilateral breast cancer. We conducted linkage analyses of 64 families with premenopausal bilateral breast cancer using DRD2, a marker linked to the ataxia-telangiectasia locus at 11q22-23. | Human | BRCA2 | 675 | breast cancer 2, early onset | BRCA1 and BRCA2 mutation status and cancer family history of Danish women affected with multifocal or bilateral breast cancer at a young age. In summary, we did not find a significantly increased prevalence of BRCA1 and BRCA2 mutations in a hospital-based cohort of German patients with bilateral breast cancer. Patients with bilateral breast cancer having BRCA2 mutations are significantly younger than non-carriers Cytogenetic heterogeneity and clonal evolution in synchronous bilateral breast carcinomas and their lymph node metastases from a male patient without any detectable BRCA2 germline mutation. Early age at diagnosis of breast cancer, ovarian cancer, bilateral breast cancer, concomitant breast/ovarian cancer in a single patient and prostate cancer but not unilateral breast cancer were associated with BRCA1 and BRCA2 mutations. BRCA1 and BRCA2 founder mutations in patients with bilateral breast cancer. To appreciate the contribution of genetic determinants to bilateral breast cancer in Jewish women we genotyped 55 such women for the three predominant mutations in BRCA1 (185delAG and 5382insC) and BRCA2 (6174delT) that account for the overwhelming majority of BRCA mutations in high-risk Jewish families. Analysis of the other Polish samples showed no correlation of the exon 8 polymorphism to breast cancer, bilateral breast cancer, BRCA1/BRCA2 mutations or age at diagnosis. Within the group of small breast-cancer-only families, a bilateral breast cancer case or a unilateral breast cancer case diagnosed before age 40 independently predicted finding a BRCA1 or BRCA2 mutation (P = 0.005 and P = 0.02, respectively). One patient with mutation 3036delACAA in BRCA2 reported only 1 sister with a multifocal bilateral breast cancer. Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer. Three BRCA2 mutations were found in patients with breast cancer without family history: two in young patients and one in patients with bilateral breast cancer. In order to test the hypothesis that BRCA1 and BRCA2 mutations are more frequent in patients with bilateral breast cancer, we have investigated a hospital-based series of 75 consecutive patients with bilateral breast cancer and a comparison group of 75 patients with unilateral breast cancer, pairwise matched by age and family history, for mutations in the BRCA1 and BRCA2 genes. In site-specific breast cancer families, mutation frequency of BRCA1 or BRCA2 was high in families with 3 or more breast cancer patients (36%, 9/25), early onset (40 < or = years old) breast cancer patients (38%, 19/50) or bilateral breast cancer patients (40%, 6/15). | Human | BRCA1 | 672 | breast cancer 1, early onset | Patients with bilateral breast cancer having BRCA1 mutations are significantly younger than non-carriers | Human | ATM | 472 | ataxia telangiectasia mutated | Finally, we report novel mutations in the ATM gene identified both in patients with ataxia-telangiectasia and in patients with unilateral or bilateral breast cancer. Results do not support association of the 5557G>A or ivs38-8T>C variant with increased breast cancer risk or with bilateral breast cancer |
|